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ABSTRACT
Objective: The present study evaluated the subchronic toxicity of Lactobacillus mediated fermented Phyllanthus emblica fruit juice (FPJ) using a rat 
as a model system.
Methods: FPJ was prepared, and estimated the changes in pH by pH meter, and microbial load by a plating method. Rats were fed with different 
dose of FPJ for 60 days. The changes in the body mass were noted. The blood and organs of the experimental rats were collected, after 60 days of 
intervention. Then, they were analyzed for the selected hematological and biochemical parameters by following standard hospital protocols.
Results: The pH of FPJ after 30 days of fermentation was 3.16. FPJ was rich in probiotic Lactobacillus spp. (7.23 Log CFU per mL) without contamination. 
The supplementation of FPJ was not significantly affected the body weight of the experimental animals, except the female rats in posteffective dose 
(PED) group showed significant changes (20.83±8.49 g) compared to control (40±17.22 g). The internal organs of the rat were not affected by 
the FPJ supplementation. The changes observed in blood urea nitrogen, creatinine, cholesterol, triglyceride, aspartate aminotransferase; alanine 
aminotransferase, and alkaline phosphatase level of experimental rats, both male and female, were not significantly differed from the respective 
controls. The average of lymphocytes level was significantly increased in continuous dosing group of males and females. Interestingly, the increase 
in red blood cell and hemoglobin (HGB) were statistically significant for ED group and PED in both sexes, except for females with no effect on HGB 
content.
Conclusion: The prepared FPJ was enriched with probiotic Lactobacillus spp. The supplementation of FPJ (up to 9 mL/kg/day) for 60 days was not 
significantly influenced the body weight, internal organs, biochemical and hematological parameters of experimental rats (both male and female). The 
results revealed that FHJ is suitable for the human consumption.
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INTRODUCTION
Phyllanthus emblica, also known as Emblica officinalis, Indian 
gooseberry, emblic, belongs to Phyllanthaceae family. P. emblica is one 
of the commonly used medicinal herbs in traditional Indian medicine. 
P. emblica is rich in phytonutrients, proteins, fibers, fat, vitamins 
(especially Vitamin-C), minerals, and trace elements (calcium, chromium, 
copper, iron, magnesium, nicotinic acid, phosphorus, potassium, and 
zinc) [1]. Almost all the part of P. emblica plant (fruit, root,and leaves) 
was reported for health benefits and pharmacological importance such 
as anti-inflammation, antihyperglycemia, anti-hyperlipidemia, anti-
cancer, anti-mutagenic, anti-pyretic, anti-microbial, anti-diarrheal, 
anti-hyperthyroidism, anti-venom cardioprotective, neuroprotective, 
etc., [2-20]. P. emblica is consumed as raw fruit, fruit juice, fermented 
fruit juice, pickles, and powder forms. P. emblica fruit pickling is most 
common practice in southern India, which has been consumed by the 
people every day along with regular diet. Southeast Asians widely 
use the fermented P. emblica fruit juice (FPJ). The fermentation of 
plant materials with desired microbial starter culture improved the 
nutritional value and bioactive compounds [21-23].
Fermentation is an ancient method of preparing, improving and 
preserving the food. Asian peoples extensively use the fermented 
foods, and they believe that fermented foods are a cure for several 
diseases [24]. The microbes isolated from naturally fermented foods 
are reported for glutaminase, and glutamate decarboxylase, and 
γ-aminobutyric acid-producing ability [25,26]. The fermented plant 
juices are reported for several pharmacological applications. For 
example, the supplementation of lactic acid bacteria (LAB) fermented 
mushroom juice help to diminish the diabetic consequences [27]. 
Lactobacillus paracasei HII01 mediated fermented P. emblica exhibited 
high polyphenolic compounds, and enhanced free-radical scavenging 
activity compared to control [21].
Though P. emblica is used in several traditional medicines, the reports 
on fermented LAB mediated FPJ is inadequate. The supplementation of 
0.5 g/kg of P. emblica leaves aqueous extract (PLAE), and 10 g/kg of an 
ethanolic extract of emblica fruit (EEEF) were not shown any toxicity in 
mice. Whereas, intraperitoneal injection of PLAE and EEEF exhibited LD50 
of 0.288–0.415, and 4.8 g/kg body weight of mice, respectively [28,29].
There was no subchronic toxicity study on LAB-mediated FPJ. The 
present study was executed to evaluate the subchronic toxicity of 




The inoculum preparation and fermentation process were performed 
as detailed in a previous study [21]. Briefly, the crushed P. emblica 
fruits, sterile water, and cane sugar were mixed in the ratio of 3:10: 1, 
and sterilized. Then, 10% of L. paracasei HII01 was inoculated, and 
fermented for 30 days.
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2018.v11i9.27104
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pH, and microbial load
The pH of FPJ was kinetically measured using pH meter (Inola, pH 
level 2, Weilheim) [21]. The microbial load of FPJ was determined by 
spread plate method using specific media as prescribed earlier [30].
Animals, intervention, and sample collection
The Sprague Dawley rats of 150–180 g of weight, obtained from National 
Laboratory Animal Center of Mahidol University, Thailand, were 
casually divided into groups. The test intervention was 1.2 mL/kg/day 
of FPJ (effective dose [ED]), 9.00 mL/kg/day of FPJ (high dose [HD]) for 
60 days, and 1.2 mL/kg/day of FPJ (post-ED [PED]) for 53 days along 
with standard animal feed. The control animals were fed with laboratory 
food and drinking water for 60 days. After 60 days of study, blood and 
internal organs of the experimental rats were collected for inspection. 
The experiments were ethically approved by the Ethical Committee of 
Faculty of Medicine, Chiang Mai University (CMU) (Approved protocol 
no: 1/2552 dated 23 June 2009).
Measurement of body mass and assessment of hematological and 
biochemical parameters
The difference in weight of experimental rats was recorded using laboratory 
weighing machine. The weight of internal organs (brain, liver, spleen, eyes, 
heart, lung, kidneys, stomach, and adrenal gland) was measured. The 
change in the weight was calculated by the following formula.
Deviations in weight = Final weight - Initial weight.
The biochemical and hematological parameters (hemoglobin [HGB], 
hematocrits, white blood cell (WBC) count, polymorphonuclear 
cell, lymphocyte, platelets, red blood cell (RBC) count, level of 
aminotransaminase, alanine aminotransaminase, alkaline phosphatase 
[ALP]) were measured at MT InterMed (Hosptial) Growth Diags 
Co., Ltd., Ching Mai, Thailand, as per the standard procedures.
Statistical analysis
The experiments were completed in triplicate. The values were 
signified as a mean ± standard deviation. Duncan’s new multiple range 
tests determined the significant differences, at the 95% confidential 
level (p<0.05) by SPSS v.17 (Chicago, SPSS Inc, U.S.A).
RESULTS AND DISCUSSION
The fermentation of P. emblica fruit juice (FPJ) was carried out. The pH 
of FPJ was gradually reduced during fermentation. The pH of initial day 
of fermentation was 3.76, while after 30 days of fermentation the pH 
was 3.16 (Fig. 1).
The microbial content of FPJ was increased during fermentation. After 
thirty days of fermentation, total bacterial count, and Lactobacillus 
spp. count was found as 7.39, and 7.23 Log CFU per mL, respectively. 
At 3–6 days of fermentation high concentration of Lactobacillus spp. 
(8.33–8.63 Log CFU per mL) was observed in FPJ. Then, the number of 
Lactobacillus spp. was reduced steadily, possibly due to the depletion of 
nutrients. Yeast and Bacillus spp. were not found in FPJ at any point of 
fermentation, which suggested that FPJ was microbiologically safe (Fig. 2).
The average body weight of ED, HD, and PED group male rats was 
104.29±31.47, 98.57±28.24, and 115.83±20.66 g, respectively, while 
control rat was 123.33±30.33 g after 60 days of the experimental period. 
The average body weight of ED, HD, and PED group female rats was 
33.57±13.14, 32.86±12.2, and 20.83±8.49 g, respectively while control 
rat was 40.00±17.22 g after 60 days of the experimental period. There 
were no significant changes in body weight of male rats supplemented 
with FPJ, irrespective of dose (ED, HD, and PED). Whereas, female rats 
in PED group showed significant changes (20.83±8.49 g) compared to 
control (40±17.22 g) (Table 1).
Animals were euthanized after the intervention of FPJ for 60 days. 
The organs (brain, eyes, heart, lung, liver, spleen, stomach, kidneys, 
and adrenal gland) were collected for macroscopic examination and 
weighed. There were no significant treatment-related pathological 
changes observed in any organ of the experimental rats at all tested 
dose levels when compared with organs in control animals (Table 2). 
The changes observed in blood urea nitrogen, creatinine, cholesterol, 
triglyceride, aspartate aminotransferase; alanine aminotransferase, 
and ALP level of experimental rats, both male and female, were not 
significantly differed from the respective controls (Table 3).
The tested hematological parameters were significantly varied from 
control (Table 3). The average of WBC, hematocrits, and platelets level 
was not altered significantly in male rats of all groups. The average 
WBC, HGB, hematocrits levels were not changed in female rats of ED 
group. The average of lymphocytes level was significantly increased 
Fig. 1: The changes in the pH of fermented Phyllanthus emblica 
fruit juice
Fig. 2: Microbial load in Phyllanthus emblica fruit juice during fermentation
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in continuous dosing group of males and females. Interestingly, the 
increase in RBC and HGB were statistically significant for ED and PED in 
both sexes, except for females with no effect on HGB content. The results 
suggested that the supplementation of FPJ affected the hematological 
parameters. However, all the changes were in the normal range. Hence, 
supplementation of FPJ was not affect the tested parameters.
The phytochemical content and medicinal property of P. emblica has 
been reported with a possible molecular mechanism [1]. P. emblica 
fruit extract exhibited cytotoxicity against ovarian, liver and cervical 
cancer cells, and the toxic effect on ovarian cancer cells was attributed 
to the activation of autophagy [31-33]. The antiproliferative effect of 
emblica extracts on cancer cell lines was associated with the activation 
of apoptotic pathway, and both crude extract and purified compounds 
(such as quercetin, corilagin, pyrogallol, ellagic, chebulagic, and gallic 
acids) can inhibit the NF-𝜅B activity [34,35].
The anti-inflammatory effect of hydroalcoholic extract of emblica 
fruit was reported using induced paw edema in rats. The emblica 
extract showed edema reduction in a dose-dependent manner, and 
results were similar to the commercial ant-inflammatory drug and 
indomethacin [36]. The methanolic extract of emblica fruits (400 mg/kg 
Table 1: The difference in body mass of test animals during the experimental period. The values were derived from the baseline values
Day Body weight (g)
Male Female
Control ED* HD** PED*** Control ED* HD** PED***
5 15.00±11.69 12.14±4.15 16.43±7.18 10.00±2.94 6.67±3.29 8.57±0.29 6.43±0.32 5.00±1.36
15 40.00±17.51 24.29±8.56 25.00±6.59 38.33±13.93 12.50±3.20 6.07±2.29 9.51±3.57 8.61±0.00
30 88.33±20.74 55.00±18.7 60.00±27.06 78.33±15.94 29.17±12.81 15.00±9.57 16.43±4.27# 13.33±7.58##
60 123.33±30.33 104.29±31.47 98.57±28.24 115.83±20.66 40.00±17.22 33.57±13.14 32.86±12.2 20.83±8.49##
*ED: 1.2 ml/kg/day, **HD: 9 ml/kg/day, ***PED: Post-effective dose (intervention has been stopped before 7 days of final assessments). #Significant difference (p<0.05) 
between control and test-group; ##significant difference (p<0.01) between control and test group. ED: Effective dose, HD: High dose
Table 2: Changes in the organ weight after oral supplementation of fermented P. emblica juice. The values were derived from the control 




1.2 ml/kg/day (ED) 9 ml/kg/day (HD) PED 1.2 ml/kg/day (ED) 9 ml/kg/day (HD) PED
Brain −0.06±0.11 −0.02±0.05 −0.26±0.43 0.01±0.02 0.02±0.10 −0.21±0.57
Eyes −0.03±0.05 −0.021±0.04 0.42±0.79 −0.02±0.07 0±0.02 0.05±0.2
Heart −0.02±0.39 0.129±0.41 0.17±0.55 −0.2±0.30 −0.22±0.24 −0.31±0.44
Lung 0.29±0.98 −0.2648±0.43 0.08±0.82 −0.19±0.43 −0.16±0.56 −0.11±0.79
Liver −0.41±2.15 −1.55±1.3 −1.09±2.38 −5.03±0.69 −4.78±0.62 −5.88±1.77
Spleen −0.09±0.09 −0.11±0.05 −0.11±0.12 −0.04±0.05 −0.12±0.22 −0.14±0.19
Stomach −0.22±±0.95 0.17±0.28 0.04±0.13 0.14±0.12 0.11±±0.11 −0.06±0.55
Kidneys −0.04±0.27 −0.13±0.23 −0.33±0.42 0.11±0.11 0.17±0.15 −0.09±0.62
Adrenal Grand −0.01±0.02 −0.02±0.02 −0.02±0.02 0.02±0.01 0.02±0.01 0±0.03
P. emblica: Phyllanthus emblica, ED: Effective dose, HD: High dose, PED: Post-effective dose
Table 3: Effect of supplementation of fermented P. emblica juice on the hematological and biochemical parameters in hamster after 
60 days of treatment. The values were derived from the control values (the difference between control value and experimental value, 
after the experimental period) and were represented as a mean±standard deviation.
Parameters Male Female
ED HD PED ED HD PED
Hematological parameters
RBC (106/mm3) −3.9±0.18** −0.26±0.19 −0.52±0.19** −0.21±0.08* −0.22±0.07 −0.23±0.12* 
WBC (103/mm3) 0.34±0.26 0.16±0.20 0.04±0.25 0.24±0.19 0.13±0.20 0.46±0.25 
HGB (g/dL) −1.08±0.61* −0.83±0.58 −1.12±0.33* −0.64±0.50 −0.16±0.58 −0.92±0.92 
Hematocrits (mL%) −3.29±1.80 −2.57±1.81 −3.33±1.03 2.50±1.47 3.42±1.26 2.17±2.74 
Lymphocyte (mL%) −7.90±3.1* −10.33±8.04* −6.16±2.64 −11.5±2.83*** −9.64±3.53** −10.00±4.37** 
Platelets (103/mm3) 15.84±11.13 15.84±11.13 15.50±19.00 −31.21±16.33* −16.93±13.95 −11.33±26.63 
Biochemical parameters
B.U.N. (mg/dL) 2.84±7.10 6.00±4.71 12.34±8.61 7.33±6.44 −4.86±2.95 2.00±4.09
Creatinine (mg/dL) 0.35±0.63 −0.14±1.24 −0.02±1.36 0.63±0.94 −0.05±1.42 0.48±1.03
Cholesterol (mg/dL) −20.00±16.34 −6.5±44.23 6.17±76.79 0.5±39.69 5.19±65.99 20.17±89.36
TG (mg/dL) −4.67±7.87 1.16±11.34 4.83±10.64 18.83±9.81 15.90±9.57 13.83±9.33 
AST (IU/L) −11.17±25.37 −24.17±29.46 −12.57±30.02 0.2±32.33 −0.71±26.37 7.6±24.96 
ALT (IU/L) −0.33±5.00 3.50±6.77 −5.33±6.71 2.33±4.37 −0.46±5.12 3.83±4.58 
ALP (IU/L) 3.08±9.06 10.58±2.94 11.08±3.71 7.77±8.73 9.74±4.71* 11.43±2.04* 
*Significant difference (p<0.05) between control and test-group, **significant difference (p<0.01) between control and test group. ***Significant difference (p<0.001) 
between control and test-group. RBC: Red blood cells, WBC: White blood cells, HGB: Hemoglobin; PMNC: Polymorphonuclear cell; BUN: Blood urea nitrogen, 
TG: Triglyceride, AST: Aspartate aminotransferase, ALT: Alanine aminotransferase, ALP: Alkaline phosphatase, ED: Effective dose, HD: High dose, PED: Post-effective 
dose, P. emblica: Phyllanthus emblica
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of body weight) reduced the carrageenan-induced acute inflammation 
in rats up to 72.71% [37].
Guo and Wang [38] reported that aqueous extract of emblica fruit 
protects the human colon epithelial cells from mitotic abnormalities, 
and genetic variability by improving the function of spindle assembly 
checkpoint. The emblica fruit extract was reported for synergetic 
antimicrobial effect along with antibiotics against Salmonella 
typhimurium [19].
The changes in phytochemical content, antioxidant property, and 
other physical properties such as color, odor, taste, and gas formation 
in LAB LPFJ was reported previously [21]. The study proved that 
L. paracasei HII01 mediated fermentation process improved the quality 
of P. emblica fruit juice regarding nutritional value and antioxidant 
property. The authors also suggested that LPFJ can be used as a dietary 
supplement [21].
CONCLUSION
As we reported earlier, the prepared FPJ was rich in phytochemicals, 
antioxidants, and free from pathogenic microbes. The supplementation 
of different dose of FHJ does not affect the average body weight 
gain, internal organs’ weight, and tested biochemical parameters 
significantly. However, hematological parameters were altered 
significantly on FHJ supplementation. The changes were within the 
normal range of respective parameters. Hence, the study suggested 
that the consumption of FPJ was not affected the rodent system in some 
disagreeable ways. The further detailed study is required to confirm the 
toxicity of FHJ.
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